Ibutilide
From Wikipedia, the free encyclopedia
Ibutilide
|
|
Systematic (IUPAC) name | |
N-[4-[4-(ethyl-heptyl-amino)- 1-hydroxy-butyl]phenyl] methanesulfonamide | |
Identifiers | |
CAS number | |
ATC code | C01 |
PubChem | |
DrugBank | |
Chemical data | |
Formula | C20H36N2O3S |
Mol. mass | 384.578 g/mol |
Pharmacokinetic data | |
Bioavailability | ? |
Protein binding | 40% |
Metabolism | ? |
Half life | ? |
Excretion | ? |
Therapeutic considerations | |
Pregnancy cat. |
? |
Legal status | |
Routes | ? |
Ibutilide (ibutilide fumarate) is a class III antiarrhythmic agent. It is associated with an extremely high rate of adverse effects, including torsades de pointes. It is not licensed for use in the UK, but is still available in the U.S.
|
|
---|---|
class Ia | Ajmaline, Disopyramide, Prajmaline, Procainamide, Quinidine, Sparteine |
class Ib | Aprindine, Lidocaine, Mexiletine, Tocainide |
class Ic | Encainide, Flecainide, Lorcainide, Moricizine, Propafenone |
class II | Propranolol, Metoprolol, Nadolol, Atenolol, Acebutolol, Pindolol see Beta blockers (C07) |
class III | Amiodarone, Bretylium tosylate, Bunaftine, Dofetilide, Ibutilide, Sotalol |
class IV | Verapamil, Diltiazem see Calcium channel blockers (C08) |
class V | Adenosine, Atropine, Digoxin |